drug regulators

Platform trials, which test multiple treatments simultaneously against a shared control group, are increasingly used in medicine and are changing how clinical evidence is generated. Critics and commentators argue that drug regulators have not adapted their evaluation frameworks to this faster, more flexible trial design, raising questions about how such evidence should be assessed and approved.

Japan is considering stricter regulations on regenerative medicine as treatments in the field proliferate across the country. The move follows growing concern that clinics are offering unproven therapies under looser rules than those governing conventional drugs. Officials are debating how to balance patient access to innovative treatments with safety oversight, and medical groups are watching closely for what the revised framework could mean for practice.